KeyBanc raises Celanese stock price target on turnaround execution

KeyBanc raised its Celanese price target to $59 from $57 and maintained an Overweight rating, citing turnaround execution and improved acetyls fundamentals. It expects EBITDA to remain flat in coming years despite easing Iran tailwinds, while deleveraging supports EPS growth, and believes the $700 million–$800 million free-cash-flow range can be raised. Separately, Celanese’s third-quarter 2026 adjusted EPS of $1.65 beat the $1.56 estimate, while revenue of $2.56 billion missed the $2.62 billion forecast.

Analysis

The equity case is increasingly a balance-sheet and cash-conversion story, not an EBITDA growth story. If operating cash flow is durable, debt reduction can lower interest burden and equity risk even with flat EBITDA; however, that benefit is gradual and can be overwhelmed by weaker acetyl pricing, volume, or working-capital outflows. The revenue miss alongside an earnings beat makes the quality of the beat important: cost actions can support near-term EPS while masking demand or pricing weakness.

The contrarian risk is that a high modeled free-cash-flow yield is being treated as a floor when it may be a cyclical peak or depend on analyst assumptions. Easing Iran-related tailwinds also means the burden shifts to underlying demand, feedstock spreads, and execution. Competitors such as Eastman face related chemical-cycle pressures, but relative performance will depend on product mix and exposure; do not assume a sector-wide read-through from CE.

Over the next 1–3 months, focus on whether cash conversion, debt reduction, and acetyl fundamentals validate the forecast rather than on incremental analyst target changes. Over 6–18 months, sustained deleveraging could justify lower perceived financial risk; a renewed spread downturn or cash-flow shortfall would instead expose the valuation to multiple compression. Verify debt trajectory, cash interest, capex/working-capital needs, and segment-level pricing before sizing a longer-term position.

Key Decisions for Investors

• No need to chase the analyst upgrades. For investors seeking exposure, consider a staged long in CE only after the next results confirm free-cash-flow conversion and net debt is declining; the thesis is falsified by flat-to-rising debt or a material deterioration in acetyl pricing/cash generation.
• Track the next quarterly revenue and segment commentary against earnings: another EPS beat driven chiefly by cost savings while revenue or pricing weakens would argue against treating the headline yield as sustainable.
• Use the next 1–3 months to verify the assumptions behind the $700–800 million cash-flow range, especially working capital, capex, and cash interest. If those disclosures are unavailable or materially weaker than modeled, keep CE on a watchlist rather than initiating.
• For a relative-value screen, compare CE with Eastman on cash conversion, leverage reduction, and chemical-cycle exposure; avoid a pair until current valuations and segment sensitivities are checked.